# A Study of Xeloda (Capecitabine) Plus Radiotherapy in Participants With Locally Advanced Rectal Cancer

> **NCT00796718** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 62 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **RADIATION:** Standard radiotherapy
- **DRUG:** Capecitabine [Xeloda]

## Key facts

- **NCT ID:** NCT00796718
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2016-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00796718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00796718, "A Study of Xeloda (Capecitabine) Plus Radiotherapy in Participants With Locally Advanced Rectal Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00796718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*